E
The Alamo San Antonio

AbbVie’s PARP inhibitor veliparib is highly active in triple negative breast cancer

The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.

December 13, 2013
E
San Antonio River Walk

What to watch for at San Antonio Breast Cancer Symposium

A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium

December 11, 2013